The clinical potential of interleukin-2

The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

R ECENT technical developments have enabled the component elements of the immune system to be separated and analyzed individually. These have restimulated investigations into the possibility that mechanisms similar to those involved in protection from microbial pathogens might be utilized to allow selective destruction of tumor cells. A major contribution has been the discovery and purification...

Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.

Concentrations of interleukin-2 (IL-2) and soluble IL-2 receptor (sIL-2R) in serum and CSF samples were measured in 63 patients with multiple sclerosis (MS) to evaluate their usefulness as markers of disease activity. CSF concentrations of IL-2 and sIL-2R were significantly higher in MS relapse compared with MS patients in remission or with control subjects. These concentrations correlated with...

Potential use of recombinant human interleukin-6 in clinical oncology.

Recombinant human IL-6 (rhIL-6) is a pleiotropic cytokine with stimulatory actions on the hematopoietic system, the immune system and hepatocytes. Clinical interest in the use of this cytokine was raised because of its thrombopoietic properties and also because of its anti-tumor activity, which was shown in vitro and in the preclinical setting. Various studies show that doses up to 10 mu kg/kg/...

Potential clinical application of interleukin-27 as an antitumor agent

Cancer immunotherapies such as sipuleucel-T and ipilimumab are promising new treatments that harness the power of the immune system to fight cancer and achieve long-lasting remission. Interleukin (IL)-27, a member of the IL-12 heterodimeric cytokine family, has pleiotropic functions in the regulation of immune responses with both pro-inflammatory and anti-inflammatory properties. Evidence obtai...

Clinical advances in therapies targeting the interleukin-2 receptor.